Fostamatinib Selected for NIH ACTIV-4 COVID-19 Clinical Trial
Go back to Fostamatinib Selected for NIH ACTIV-4 COVID-19 Clinical Trial| Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) | Delayed: 45.89 +0.64 (1.41%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $45.25 | 52 Week High | $4.38 | |||
| Open | $45.74 | 52 Week Low | $1.88 | |||
| Day High | $46.49 | P/E | N/A | |||
| Day Low | $45.00 | EPS | $-1.12 | |||
| Volume | 322,084 | |||||
